Evotec Collaborates to Uncover New Therapeutic Targets in Obesity and Metabolic Diseases

Evotec SE, in collaboration with Inserm, Lille University Hospital, and Inserm Transfert, has announced a new partnership aimed at identifying novel therapeutic targets for obesity and metabolic diseases. This collaboration will leverage Evotec's PanOmics technologies to generate extensive omics data sets, enhancing the understanding of disease mechanisms.

Lille University Hospital will contribute human biological samples and clinical data from its ABOS Biobank, aiding in the collection of specific biosamples for the study. The goal is to understand and validate key mechanisms of obesity and other metabolic conditions.

Under the agreement, Evotec will access a significant cohort of over 8,000 human samples, supporting research into the molecular drivers of diseases such as metabolic dysfunction-associated steatohepatitis, diabetes, and cardiovascular conditions. This data will feed into Evotec's E.MPD platform for analysis.

Dr. Cord Dohrmann, CSO of Evotec, emphasized that collaborating with Inserm and Lille University Hospital will enhance the characterization of obesity, aiming to find effective and safer treatments. The partnership expects to make significant strides in treating obesity and its comorbidities.